Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Vaginal Adaptive Immunity Against Zika Virus

Award Number: R21AI140063
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/06/2018
PERIOD OF PERFORMANCE END DATE: 05/31/2020

Group Awards By:

View Award Description

Vaginal Adaptive Immunity Against Zika Virus - PROJECT SUMMARY Case reports of Zika virus (ZIKV) sexual transmission are mounting. Early epidemiologic studies demonstrate a higher incidence of ZIKV in women and also appear to demonstrate regional disparities in the clinical severity of Zika disease. These latter findings combined with laboratory reports indicate that prior immunity to dengue virus (DENV) or other related viruses and vaccines may modulate subsequent ZIKV infection. ZIKV persists in semen for up to 6 months and the vagina for up to 14 days. The most devastating outcomes of human ZIKV infection result from transmission of the virus from women to their fetuses. Thus, vaginal immunity emerges as a critical barrier to both stop the ZIKV transmission cycle, and to prevent a step towards eventual transmission to the fetus. Yet little is known about which mechanisms contribute to vaginal anti-ZIKV immunity and the roles that preexisting immunity to ZIKV or DENV play against subsequent vaginal ZIKV infection (vagZIKV). Recent studies from our lab and others using mouse models demonstrated that ZIKV replicates in the mouse vagina and that even a wild-type vaginal antiviral response is initially incompetent in controlling vagZIKV. Because DENV and ZIKV are highly cross-reactive and vaginal immunity is mediated in part by antibodies, it seems reasonable to speculate that antibodies would mediate cross-protection in the vagina. However, our recent data demonstrate that DENV/ZIKV-cross-reactive CD8 T cells dominate during subsequent systemic ZIKV infection, and that DENV-immune CD8 T cells are both necessary and sufficient to provide cross-protection against systemic ZIKV infection. Therefore, the goals of this project are (i) to evaluate the role of the CD8 T cell response in protection against vagZIKV. (Specific Aim 1) and (ii) To investigate how changes in prior ZIKV/DENV infection route/dose affect subsequent anti-ZIKV CD8 T cell responses, including primary effectors and various memory subsets (effector, central, and resident memory), and protection against vagZIKV (Specific Aim 2).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	2	11/20/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $225,000 )
2019	2019	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	2	7/18/2019	NON-COMPETING CONTINUATION	$225,000
														Subtotal = $225,000

Issue Date FY: 2018 ( Subtotal = $270,000 )
2018	2018	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	1	6/5/2018	NEW	$270,000
														Subtotal = $270,000

Grand Total All Awards = $495,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Vaginal Adaptive Immunity Against Zika Virus

Award Number: R21AI140063

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/06/2018

PERIOD OF PERFORMANCE END DATE: 05/31/2020

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer